Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1,185 USD | -0,42 % | +1,61 % | -62,02 % |
Resumen de negocios
Número de empleados: 11
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jacques Suzanne
CEO | Chief Executive Officer | 53 | 28/03/22 |
Founder | 79 | 01/09/15 | |
Wendy DiCicco
DFI | Director of Finance/CFO | 56 | 19/07/23 |
Miles Nunn
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/15 |
John Neylan
CTO | Chief Tech/Sci/R&D Officer | 70 | 08/11/22 |
Chief Operating Officer | - | 01/07/22 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Donald Williams
BRD | Director/Board Member | 65 | 01/06/16 |
Founder | 79 | 01/09/15 | |
Director/Board Member | 61 | 05/07/23 | |
Samir R. Patel
BRD | Director/Board Member | 55 | 29/11 |
Director/Board Member | 70 | 23/01/18 | |
Jacques Suzanne
CEO | Chief Executive Officer | 53 | 28/03/22 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 13 234 315 298 | 3 808 858 604 ( 28,78 %) | 0 | 28,78 % |
Información de la empresa
Akari Therapeutics Plc
22 Boston Wharf Road 7th Floor
02210, Boston
+44 20 8004 0270
http://www.akaritx.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
-62,02 % | 9,39 M | |
-2,31 % | 103 mil M | |
+0,56 % | 95,28 mil M | |
+1,69 % | 22,15 mil M | |
-17,37 % | 21,02 mil M | |
-9,30 % | 18,15 mil M | |
-41,01 % | 16,74 mil M | |
-14,85 % | 16,05 mil M | |
+3,21 % | 13,68 mil M | |
+33,54 % | 12,17 mil M |
- Bolsa de valores
- Acciones
- Acción AKTX
- Empresa Akari Therapeutics, Plc